Biotech | December 11, 2021
Alembic acquires stake in RIGlmmune
The company is focused on the development of novel treatments for RNA viruses
The company is focused on the development of novel treatments for RNA viruses
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
Organised by the Indian Stroke Association, it has attracted over 800 doctors from India and overseas
The facility will supply clinical trial materials for the development of vaccines and biologics up to Phase II stage and is expected to be fully operational by early 2023.
It works with Pfizer to support more rapid innovation and improved clinical manufacturing operations to help develop tomorrow’s therapies
The recommendation was made by the Indian SARS-CoV-2 Genomics Sequencing Consortium (INSACOG), a network of national testing labs set up by the government to monitor genomic variations of Covid-19
Vaccine effectiveness of complete vaccination against the moderate-to-severe disease was at 81 per cent
Owkin builds best-in-class predictive biomedical AI models and robust data sets
State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem
The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis
Subscribe To Our Newsletter & Stay Updated
